Premium
Transporters in Drug Development: 2018 ITC Recommendations for Transporters of Emerging Clinical Importance
Author(s) -
ZamekGliszczynski Maciej J.,
Taub Mitchell E.,
Chothe Paresh P.,
Chu Xiaoyan,
Giacomini Kathleen M.,
Kim Richard B.,
Ray Adrian S.,
Stocker Sophie L.,
Unadkat Jashvant D.,
Wittwer Matthias B.,
Xia Cindy,
Yee SookWah,
Zhang Lei,
Zhang Yan
Publication year - 2018
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.1112
Subject(s) - transporter , organic anion transporter 1 , organic cation transport proteins , drug , organic anion transporting polypeptide , pharmacology , drug development , disposition , medicine , chemistry , biochemistry , psychology , gene , social psychology
This white paper provides updated International Transporter Consortium (ITC) recommendations on transporters that are important in drug development following the 3 rd ITC workshop. New additions include prospective evaluation of organic cation transporter 1 (OCT1) and retrospective evaluation of organic anion transporting polypeptide (OATP)2B1 because of their important roles in drug absorption, disposition, and effects. For the first time, the ITC underscores the importance of transporters involved in drug‐induced vitamin deficiency (THTR2) and those involved in the disposition of biomarkers of organ function (OAT2 and bile acid transporters).